Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 13/20 | 0.74 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.69 |
| ▸ | PTP4A2 | Q12974 | 1/20 | 0.69 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 8/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323039 | 0.82 | PTP4A3 (1.00) | GSK3BPTP4A3PTP4A2PTP4A1RAB9A | |
| SCHEMBL21963445 | 0.77 | PTP4A3 (0.63) | GSK3BPTP4A3PTP4A2PTP4A1RAB9A | |
| SCHEMBL22107527 | 0.75 | PTP4A3 (0.44) | GSK3BPTP4A3PTP4A2PTP4A1RAB9A | |
| SCHEMBL21963447 | 0.74 | PTP4A3 (0.59) | GSK3BPTP4A3PTP4A2PTP4A1RAB9A | |
| SCHEMBL4349967 | 0.72 | GSK3B (0.54) | GSK3BPTP4A3PTP4A2PTP4A1ALDH1A1 | |
| SCHEMBL2236236 | 0.70 | CYP1A1 (0.55) | PTP4A3PTP4A2PTP4A1RAB9AALDH1A1 | |
| SCHEMBL15716938 | 0.70 | GSK3B (0.51) | GSK3BPTP4A3PTP4A2PTP4A1ALDH1A1 | |
| SCHEMBL4515919 | 0.70 | RAB9A (0.55) | PTP4A3PTP4A2PTP4A1RAB9AALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL15716761 | 0.70 | GSK3B (0.51) | GSK3BPTP4A3PTP4A2PTP4A1ALDH1A1 | |
| SCHEMBL4345561 | 0.69 | GSK3B (0.41) | GSK3BPTP4A3PTP4A2PTP4A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1556053-A4 | ANTIINFLAMMATION AGENTS | AMGEN INC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1556053-A1 | ANTIINFLAMMATION AGENTS | Amgen Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041285-A1 | ANTIINFLAMMATION AGENTS | AMGEN INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097485-A1 | Antiinflammation agents | TULARIK INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155777-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | GSK3B 1989/4885PTP4A3 3920/4885PTP4A2 3329/4885 |
| US-20040097485-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | GSK3B 1989/4885PTP4A3 3920/4885PTP4A2 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.